<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02173691</url>
  </required_header>
  <id_info>
    <org_study_id>205.137</org_study_id>
    <nct_id>NCT02173691</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Tiotropium Compared to Salmeterol and Placebo in Patients With Chronic Obstructive Bronchitis (COPD)</brief_title>
  <official_title>A Multiple Dose Comparison of Tiotropium Inhalation Capsules, Salmeterol Inhalation Aerosol and Placebo in a Six-Month, Double-Blind, Double-Dummy, Safety and Efficacy Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the long-term (six month) bronchodilator efficacy&#xD;
      and safety of tiotropium inhalation capsules, salmeterol inhalation aerosol and placebo&#xD;
      inpatients with COPD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 1999</start_date>
  <primary_completion_date type="Actual">May 2000</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trough forced expiratory volume in one second (FEV1) response</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Transition Dyspnoea Index (TDI) focal score</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average FEV1 response</measure>
    <time_frame>30 and 60 min prior to and 30 and 60 min, 2 and 3 h post treatment on day 1, week 2, 8, 16, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 response</measure>
    <time_frame>30 and 60 min prior to and 30 and 60 min, 2 and 3 h post treatment on day 1, week 2, 8, 16, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC (forced vital capacity) response</measure>
    <time_frame>30 and 60 min prior to and 30 and 60 min, 2 and 3 h post treatment on day 1, week 2, 8, 16, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average FVC (forced vital capacity) response</measure>
    <time_frame>30 and 60 min prior to and 30 and 60 min, 2 and 3 h post treatment on day 1, week 2, 8, 16, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FVC (forced vital capacity) response</measure>
    <time_frame>30 and 60 min prior to and 30 and 60 min, 2 and 3 h post treatment on day 1, week 2, 8, 16, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual FEV1 measurement</measure>
    <time_frame>Day 1, weeks 2, 8, 16, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual FVC measurement</measure>
    <time_frame>Day 1, weeks 2, 8, 16, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient peak expiratory flow rates (PEFR) twice daily</measure>
    <time_frame>27 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's global evaluation on an 8-point-scale</measure>
    <time_frame>27 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COPD symptom scores (wheezing, shortness of breath, coughing and tightness of chest)</measure>
    <time_frame>27 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of salbutamol therapy used during the treatment period</measure>
    <time_frame>27 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and length of exacerbations of COPD</measure>
    <time_frame>27 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and length of hospitalizations for respiratory disease</measure>
    <time_frame>27 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in St. George's Hospital Respiratory Questionnaire (SGRQ)</measure>
    <time_frame>Day 1, week 8, 16, 24 and 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Mahler Dyspnoea Index (Baseline Dyspnoea Index /Transitional Dyspnoea Index (BDI/TDI))</measure>
    <time_frame>Baseline, week 8, 16, 24, 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health resource utilisation</measure>
    <time_frame>27 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient preference measures</measure>
    <time_frame>Day 1 and week 24</time_frame>
    <description>patient satisfaction questionnaire score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Shuttle walking tests (SWT) and Borg dyspnea score</measure>
    <time_frame>Day 1, week 8, 16, 24, 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Adverse Events</measure>
    <time_frame>27 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in pulse rate and blood pressure in conjunction with spirometry</measure>
    <time_frame>baseline, Day 1, week 2, 8, 16 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in physical examination and ECG</measure>
    <time_frame>baseline and week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in laboratory tests</measure>
    <time_frame>baseline and week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">584</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Tiotropium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Salmeterol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium inhalation powder capsules</intervention_name>
    <arm_group_label>Tiotropium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salmeterol inhalation aerosol</intervention_name>
    <arm_group_label>Salmeterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo inhalation aerosol</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Tiotropium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo inhalation powder capsules</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Salmeterol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 40 years.&#xD;
&#xD;
          -  A diagnosis of relatively stable, moderate to severe COPD with:&#xD;
&#xD;
               -  Screening FEV1 ≤ 60% of predicted normal value (calculated according to European&#xD;
                  Community for Coal and Steel (ECCS) criteria and screening FEV1/FVC ≤ 70%&#xD;
&#xD;
          -  Smoking history ≥ 10 pack-years (a pack-year is 20 cigarettes per day for one year or&#xD;
             equivalent)&#xD;
&#xD;
          -  Ability to be trained in the proper use of the HandiHaler® device and Metered Dose&#xD;
             Inhaler (MDI).&#xD;
&#xD;
          -  Ability to perform all study related tests including the Shuttle Walking Test,&#xD;
             acceptable pulmonary function tests, including Peak expiratory flow rate (PEFR)&#xD;
             measurements, and maintenance of diary card records.&#xD;
&#xD;
          -  Ability to give written informed consent in accordance with Good Clinical Practice and&#xD;
             local regulations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant diseases other than COPD.&#xD;
&#xD;
          -  Patients with clinically relevant abnormal baseline haematology, blood chemistry or&#xD;
             urinalysis, if the abnormality defines a disease listed as an exclusion criterion,&#xD;
             will be excluded.&#xD;
&#xD;
          -  All patients with a serum glutamic oxaloacetic transaminase (SGOT) &gt; 80 IU/L, serum&#xD;
             glutamic pyruvic transaminase (SGPT) &gt; 80 IU/L, bilirubin &gt;2.0 mg/dL or creatinine &gt;&#xD;
             2.0 mg/dL will be excluded regardless of clinical condition.&#xD;
&#xD;
          -  A recent history (i.e., one year or less) of myocardial infarction.&#xD;
&#xD;
          -  Any cardiac arrhythmia requiring drug therapy or hospitalisation for heart failure&#xD;
             within the past three years.&#xD;
&#xD;
          -  Inability to abstain from regular daytime use of oxygen therapy for more than 1 hour&#xD;
             per day.&#xD;
&#xD;
          -  Known active tuberculosis.&#xD;
&#xD;
          -  History of cancer within the last five years (excluding basal cell carcinoma)&#xD;
&#xD;
          -  History of life-threatening pulmonary obstruction, or a history of cystic fibrosis or&#xD;
             bronchiectasis.&#xD;
&#xD;
          -  Patients who have undergone thoracotomy with pulmonary resection.&#xD;
&#xD;
          -  Any upper respiratory infection in the past six weeks prior to the screening visit or&#xD;
             during the run-in period.&#xD;
&#xD;
          -  Current participation in a pulmonary rehabilitation programme or completion of a&#xD;
             pulmonary rehabilitation programme in the six week prior to the screening visit.&#xD;
&#xD;
          -  Known hypersensitivity to anticholinergic drugs, salmeterol, or any of the components&#xD;
             of the lactose powder capsule or MDI delivery systems.&#xD;
&#xD;
          -  Known symptomatic prostatic hypertrophy or bladder neck obstruction.&#xD;
&#xD;
          -  Patients with known narrow-angle glaucoma.&#xD;
&#xD;
          -  Current treatment with cromolyn sodium or nedocromil sodium.&#xD;
&#xD;
          -  Current treatment with antihistamines (H1 receptor antagonists).&#xD;
&#xD;
          -  Oral corticosteroid medication at unstable doses (i.e., less than six weeks on a&#xD;
             stable dose) or at doses in excess of the equivalent of 10 mg of prednisolone per day&#xD;
             or 20 mg every other day.&#xD;
&#xD;
          -  Current use of β-blocker medication.&#xD;
&#xD;
          -  Current treatment with monoamine oxidase inhibitors or tricyclic antidepressants.&#xD;
&#xD;
          -  Pregnant or nursing women or women of childbearing potential not using a medically&#xD;
             approved means of contraception.&#xD;
&#xD;
          -  Patients with a history of asthma, allergic rhinitis or atopy or who have a total&#xD;
             blood eosinophil count &gt; 600mm3.&#xD;
&#xD;
          -  History of and/or active significant alcohol or drug abuse.&#xD;
&#xD;
          -  Concomitant or recent use of an investigational drug within one month or six half&#xD;
             lives (whichever is greater) prior to the screening visit.&#xD;
&#xD;
          -  Changes in the pulmonary therapeutic plan within the six weeks prior to the screening&#xD;
             visit.&#xD;
&#xD;
          -  Inability to comply with the medication restrictions specified in Section 4.2 of the&#xD;
             trial protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/205/205.137_U01-1231-02.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2014</study_first_posted>
  <last_update_submitted>June 25, 2014</last_update_submitted>
  <last_update_submitted_qc>June 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

